PASADENA, Calif.–(BUSINESS WIRE)–$arwr–Arrowhead Prescribed drugs Inc. (NASDAQ: ARWR) at the moment introduced further optimistic interim 48-week liver biopsy outcomes from the continued AROAAT2002 examine, an open-label Part 2 scientific examine of ARO-AAT, the corporate’s second technology investigational RNA interference (RNAi) therapeutic being co-developed with Takeda Pharmaceutical Firm Restricted (“Takeda”) as a therapy for the uncommon genetic liver illness related to alpha-1 antitrypsin deficiency (AATD), at The Worldwide Liver Congress – The Annual Assembly of the European Affiliation for the Research of the Liver (EASL).
The outcomes exhibit that, within the AROAAT2002 examine, investigational ARO-AAT therapy led to enhancements in a number of measures of liver well being, together with fibrosis, with substantial and sustained reductions within the degree of mutant AAT protein (Z-AAT). As well as, ARO-AAT therapy was usually properly tolerated after as much as 1 yr of therapy.
Javier San Martin, M.D., chief medical officer at Arrowhead, mentioned: “We consider the interim outcomes that have been introduced at the moment at EASL characterize an vital breakthrough for the sector and are encouraging for sufferers with alpha-1 liver illness, who presently don’t have any obtainable therapy choices apart from liver transplant. The information point out that therapy with investigational ARO-AAT, being developed in collaboration with Takeda as TAK-999, resulted in substantial, sustained, and constant reductions within the manufacturing of the poisonous mutant Z-AAT protein, which has been recognized as the reason for progressive liver illness in sufferers with alpha-1 antitrypsin deficiency. This discount over 6 and 12 months led to a number of vital indicators related to therapeutic of sufferers’ liver illness. Importantly, we consider ARO-AAT is the primary investigational remedy to indicate any such profit in sufferers with alpha-1 liver illness. We need to thank all of the investigators and sufferers for his or her participation within the examine, and we look ahead to the supply of further outcomes from this examine and from our ongoing SEQUOIA examine of ARO-AAT, which we anticipate will attain full enrollment in the course of the third quarter of 2021.”
Pharmacodynamics and Efficacy
After 24 weeks (cohort 1, n=4) and 48 weeks (cohort 2, n=5) of therapy with investigational ARO-AAT within the AROAAT2002 examine, the next outcomes have been noticed:
- Serum Z-AAT ranges decreased in all sufferers
Median lower in intra-hepatic Z-AAT ranges have been:
- Whole Z-AAT -80.1% (vary -72 to -97%)
- Monomer -90% (vary -79 to -97%)
Polymer -81% (vary* -42 to -97%)
- *Excluding 1 topic in cohort 1 that had very low Z-AAT polymer ranges at baseline that elevated at week 24
- Histological globule burden was diminished in all 9 sufferers, with two attaining full decision (complete mixture globule burden rating=0)
Six of the 9 sufferers (2/4 after 24 weeks and 4/5 after 48 weeks) achieved a 1 or larger stage enchancment in Metavir fibrosis stage, with no worsening of fibrosis within the different three sufferers
- Two sufferers had baseline F4 fibrosis (cirrhosis), with one affected person attaining a two-stage enchancment to F2 and the opposite affected person attaining a one-stage enchancment to F3
- A number of biomarkers of liver well being improved, together with liver stiffness (FibroScan), liver enzymes alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT), and PRO-C3, a marker of collagen formation
Security and Tolerability
In AROAAT2002, investigational ARO-AAT demonstrated an appropriate security profile and was usually properly tolerated after as much as 1 yr of therapy. There have been no treatment-emergent opposed occasions resulting in drug discontinuation, dose interruptions, or examine withdrawal. Lung operate was assessed all through the examine and there have been no clinically significant modifications in p.c predicted pressured expiratory quantity in 1 second (ppFEV1). Three severe opposed occasions (SAEs) have been reported, however none have been thought-about associated to the examine drug. All SAEs have been reasonable in severity and all resolved.
AROAAT2002 (NCT03946449) is a pilot open-label, multi-dose, Part 2 examine to evaluate the response to investigational ARO-AAT in 16 sufferers with AATD related liver illness and baseline liver fibrosis. All eligible individuals obtain a pre-dose biopsy and an finish of examine biopsy. Handled individuals can even be supplied the chance to proceed therapy in an open-label extension (OLE). Together with the OLE, interim assessments shall be made after 6 months, 12 months, 18 months, and 24 months of therapy with ARO-AAT.
Title: ARO-AAT an investigational RNAi therapeutic demonstrates enchancment in liver fibrosis with discount in intra-hepatic Z-AAT burden
Authors: Pavel Strnad, et al.
Sort: Late-Breaking Oral Presentation
Date and Time: June 26, 2021 at 12:15 CEST
A replica of the presentation supplies could also be accessed on the Occasions and Displays web page beneath the Buyers part of the Arrowhead web site.
About Arrowhead and Takeda Collaboration
In October 2020, Arrowhead and Takeda introduced a collaboration and licensing settlement to develop investigational ARO-AAT. Underneath the phrases of the settlement, Arrowhead and Takeda will co-develop ARO-AAT which, if authorized, shall be co-commercialized in the US beneath a 50/50 profit-sharing construction. Exterior the U.S., Takeda will lead the worldwide commercialization technique and obtain an unique license to commercialize ARO-AAT with Arrowhead eligible to obtain tiered royalties of 20-25% on internet gross sales. Arrowhead obtained an upfront fee of $300 million and is eligible to obtain potential improvement, regulatory and industrial milestones of as much as $740 million.
About Alpha-1 Antitrypsin-Related Liver Illness
Alpha-1 Antitrypsin-Related Deficiency (AATD) is a uncommon genetic dysfunction related to liver illness in youngsters and adults and pulmonary illness in adults. AATD is estimated to have an effect on 1 per 3,000-5,000 folks in the US and 1 per 2,500 in Europe. The protein AAT is primarily synthesized and secreted by hepatocytes. Its operate is to inhibit enzymes that may break down regular connective tissue. The most typical illness variant, the Z mutant, has a single amino acid substitution that leads to improper folding of the protein. The mutant protein can’t be successfully secreted and accumulates in globules contained in the hepatocytes. This triggers steady hepatocyte harm, resulting in fibrosis, cirrhosis, and elevated danger of hepatocellular carcinoma.
People with the homozygous PiZZ genotype have extreme deficiency of practical AAT resulting in pulmonary illness and liver illness. Lung illness is continuously handled with AAT augmentation remedy. Nevertheless, augmentation remedy does nothing to deal with liver illness, and there’s no particular remedy for hepatic manifestations. There’s a vital unmet want as liver transplant, with its attendant morbidity and mortality, is presently the one obtainable remedy.
About Arrowhead Prescribed drugs
Arrowhead Prescribed drugs develops medicines that deal with intractable ailments by silencing the genes that trigger them. Utilizing a broad portfolio of RNA chemistries and environment friendly modes of supply, Arrowhead therapies set off the RNA interference mechanism to induce fast, deep, and sturdy knockdown of goal genes. RNA interference, or RNAi, is a mechanism current in residing cells that inhibits the expression of a particular gene, thereby affecting the manufacturing of a particular protein. Arrowhead’s RNAi-based therapeutics leverage this pure pathway of gene silencing.
For extra data, please go to www.arrowheadpharma.com, or observe us on Twitter @ArrowheadPharma. To be added to the Firm’s e-mail listing and obtain information straight, please go to http://ir.arrowheadpharma.com/email-alerts.
Secure Harbor Assertion beneath the Non-public Securities Litigation Reform Act:
This information launch accommodates forward-looking statements inside the which means of the “secure harbor” provisions of the Non-public Securities Litigation Reform Act of 1995. Any statements contained on this launch apart from historic data could also be deemed to be forward-looking statements. With out limiting the generality of the foregoing, phrases corresponding to “could,” “will,” “count on,” “consider,” “anticipate,” “intend,” “plan,” “venture,” “may,” “estimate,” or “proceed” are supposed to establish such forward-looking statements. As well as, any statements that discuss with projections of our future monetary efficiency, developments in our enterprise, expectations for our product pipeline, prospects or advantages of our collaborations with different corporations, or different characterizations of future occasions or circumstances are forward-looking statements. These statements are primarily based upon our present expectations and communicate solely as of the date hereof. Our precise outcomes could differ materially and adversely from these expressed in any forward-looking statements on account of quite a few elements and uncertainties, together with the influence of the continued COVID-19 pandemic on our enterprise, the protection and efficacy of our product candidates, the length and influence of regulatory delays in our scientific applications, our skill to finance our operations, the chance and timing of the receipt of future milestone and licensing charges, the longer term success of our scientific research, our skill to efficiently develop and commercialize drug candidates, the timing for beginning and finishing scientific trials, fast technological change in our markets, the enforcement of our mental property rights, and the opposite dangers and uncertainties described in our most up-to-date Annual Report on Kind 10-Ok, subsequent Quarterly Stories on Kind 10-Q and different paperwork filed with the Securities and Trade Fee infrequently. We assume no obligation to replace or revise forward-looking statements to replicate new occasions or circumstances.
Supply: Arrowhead Prescribed drugs, Inc.
Arrowhead Prescribed drugs, Inc.
Vince Anzalone, CFA
LifeSci Advisors, LLC
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.